These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 35356990)

  • 21. A Cost-per-Number Needed to Treat Analysis Assessing the Efficiency of Biologic Drugs in Moderate to Severe Plaque Psoriasis.
    Núñez M; Huete T; de la Cueva P; Sacristán JA; Hartz S; Dilla T
    Actas Dermosifiliogr (Engl Ed); 2019 Sep; 110(7):546-553. PubMed ID: 30851873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
    Loos AM; Liu S; Segel C; Ollendorf DA; Pearson SD; Linder JA
    J Am Acad Dermatol; 2018 Jul; 79(1):135-144.e7. PubMed ID: 29438757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.
    Warren RB; Gooderham M; Burge R; Zhu B; Amato D; Liu KH; Shrom D; Guo J; Brnabic A; Blauvelt A
    J Am Acad Dermatol; 2020 May; 82(5):1138-1149. PubMed ID: 31884091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.
    Al Sawah S; Foster SA; Burge R; Amato D; Schacht A; Zhu B; Hartz S; Leonardi C
    J Med Econ; 2017 Dec; 20(12):1224-1230. PubMed ID: 28760056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
    Hampton P; Halliday A; Aassi M; Subramanian S; Jain M; Griffiths CEM
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):928-937. PubMed ID: 33030755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS).
    Gargiulo L; Ibba L; Malagoli P; Angileri RG; Bardazzi F; Bernardini N; Burlando M; Carrera CG; Chiricozzi A; Dapavo P; Dini V; Fabbrocini G; Gaiani FM; Galluzzo M; Giofré C; Guarneri C; Loconsole F; Malara G; Marcelli L; Megna M; Piaserico S; Talamonti M; Costanzo A; Narcisi A
    J Eur Acad Dermatol Venereol; 2023 May; 37(5):1017-1027. PubMed ID: 36695061
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Frequency and outcomes of treatment dose escalation with biologics in moderate-to-severe psoriasis: a Swedish register study.
    Svedbom A; Wennerström C; Hjelm F; Tjärnlund A; Ståhle M
    J Dermatolog Treat; 2024 Dec; 35(1):2398170. PubMed ID: 39229963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis: a systematic review.
    Blauvelt A; Burge R; Malatestinic W; Brnabic A; Guo J; Janardhanan M; Zhu B
    J Manag Care Spec Pharm; 2021 Jan; 27(1):84-94. PubMed ID: 33377444
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparative effectiveness of adalimumab versus ustekinumab in the treatment of severe chronic plaque psoriasis: The results based on data from the program "treatment of moderate and severe forms of plaque psoriasis (B.47)" of the National Health Fund in Poland.
    Owczarek W; Nowakowska A; Walecka I; Ciechanowicz P; Reich A; Lesiak A; Borkowska E; Śliwczyński A; Narbutt J
    Dermatol Ther; 2022 Jun; 35(6):e15481. PubMed ID: 35363386
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network meta-analysis of randomized clinical trials.
    Spencer RK; Jin JQ; Elhage KG; Davis MS; Hakimi M; Bhutani T; Liao W
    J Am Acad Dermatol; 2023 Aug; 89(2):423-425. PubMed ID: 37121476
    [No Abstract]   [Full Text] [Related]  

  • 31. Female patients are less satisfied with biological treatment for psoriasis and experience more side-effects than male patients: results from the prospective BioCAPTURE registry.
    van der Schoot LS; van den Reek JMPA; Groenewoud JMM; Otero ME; Njoo MD; Ossenkoppele PM; Mommers JM; Koetsier MIA; Berends MAM; Arnold WP; Peters B; Andriessen MPM; Den Hengst CW; Kuijpers ALA; de Jong EMGJ
    J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):1913-1920. PubMed ID: 31177583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review.
    Sanchez IM; Sorenson E; Levin E; Liao W
    Dermatol Ther (Heidelb); 2017 Dec; 7(4):425-446. PubMed ID: 29143230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases.
    Takahashi N; Noda S; Taniguchi T; Adachi M
    Int J Dermatol; 2015 Oct; 54(10):1194-8. PubMed ID: 26016819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Onset of Action of Biologics in Patients With Moderate-to-Severe Psoriasis.
    Papp KA; Lebwohl MG
    J Drugs Dermatol; 2018 Mar; 17(3):247-250. PubMed ID: 29537442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Bai F; Li GG; Liu Q; Niu X; Li R; Ma H
    J Immunol Res; 2019; 2019():2546161. PubMed ID: 31583255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis.
    Graier T; Salmhofer W; Jonak C; Weger W; Kölli C; Gruber B; Sator PG; Prillinger K; Mlynek A; Schütz-Bergmayr M; Richter L; Ratzinger G; Painsi C; Selhofer S; Häring N; Wippel-Slupetzky K; Skvara H; Trattner H; Tanew A; Inzinger M; Tatarski R; Bangert C; Ellersdorfer C; Lichem R; Gruber-Wackernagel A; Hofer A; Legat F; Schmiedberger E; Strohal R; Lange-Asschenfeldt B; Schmuth M; Vujic I; Hoetzenecker W; Trautinger F; Saxinger W; Müllegger R; Quehenberger F; Wolf P
    Br J Dermatol; 2021 Jun; 184(6):1094-1105. PubMed ID: 33289075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis.
    Yiu ZZN; Mason KJ; Barker JNWN; Hampton PJ; McElhone K; Smith CH; Warren RB; Griffiths CEM; Lunt M; Burden AD;
    Br J Dermatol; 2019 Dec; 181(6):1265-1271. PubMed ID: 30822358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and Safety of Adalimumab, Etanercept and Ustekinumab for Severe Psoriasis in Children Under 12 Years of Age: A French-Italian Daily Practice Cohort (BiPe Jr).
    Zitouni J; Beauchet A; Curmin R; Di Lernia V; Bursztejn AC; Mazereeuw-Hautier J; Gottlieb J; Lasek A; Aubert H; Droitcourt C; Bulai-Livideanu C; Fortina AB; Caroppo F; Quiles-Tsimaratos N; Mallet S; Barthélémy H; Puzenat E; Bouilly-Auvray D; Neri I; Phan C; Mahé E;
    Paediatr Drugs; 2022 May; 24(3):281-292. PubMed ID: 35397731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry.
    Zweegers J; van den Reek JM; van de Kerkhof PC; Otero ME; Kuijpers AL; Koetsier MI; Arnold WP; Berends MA; Weppner-Parren L; Ossenkoppele PM; Njoo MD; Mommers JM; van Lümig PP; Driessen RJ; Kievit W; de Jong EM
    Br J Dermatol; 2016 Aug; 175(2):340-7. PubMed ID: 26989852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis.
    Wu JJ; Jia X; Zhao Y; Carrico J; Brodtkorb TH; Mendelsohn A; Lowry S; Feldman SR; Armstrong A
    J Dermatolog Treat; 2021 Nov; 32(7):693-700. PubMed ID: 32233828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.